Shopping Cart
Remove All
Your shopping cart is currently empty
Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $923 | - | In Stock | |
| 5 mg | $2,540 | - | In Stock | |
| 10 mg | $3,420 | - | In Stock | |
| 25 mg | $4,970 | - | In Stock |
| Description | Mirvetuximab soravtansine (IMGN853) is an antibody-drug coupling (ADC) targeting folate receptor alpha (FRα), which inhibits cell growth and enhances the antiproliferative effects of DNA damage, and may be useful in the study of drug-resistant ovarian cancer. |
| In vitro | 8 nM Mirvetuximab soravtansine in combination with Carboplatin treated IGROV-1 cells showed enhanced synergistic inhibition of growth and disruption of the cell cycle in vitro. [1] |
| In vivo | Intravenous injection of 5 mg/kg Mirvetuximab soravtansine enhances the antitumor effect of Carboplatin in vivo using a xenograft model derived from SCID female mouse patients. [1] |
| Synonyms | TAK-853, IMGN-853, IMGN853 |
| Molecular Weight | 150000 (average) |
| Cas No. | 1453084-37-1 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.